- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Lacrimal gland histopathology and secretory function in Sj (Pubmed Central) - Mar 9, 2023 This data emphasizes the safety of perioperative DM application in pLGG, adding further evidence for decision making and requested future guidelines. The administration of Moringa oleifera leaf extract 200 mg/kg BW for 14 days could significantly improve lacrimal gland histopathology but was not effective in increasing tear production in Sj
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Stem Cell Transplantation in Crohn's Disease (clinicaltrials.gov) - Mar 9, 2023 P1/2, N=15, Recruiting, Recognition and appropriate treatment of acute myocardial injury episodes in DMD patients may delay the development of cardiomyopathy. Trial primary completion date: Jan 2023 --> Jan 2024
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Window-2: Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 9, 2023 P2, N=50, Active, not recruiting, Trial completion date: Nov 2022 --> Mar 2023 Trial completion date: May 2023 --> May 2025 | Trial primary completion date: Apr 2023 --> May 2025
- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease (clinicaltrials.gov) - Mar 9, 2023 P1, N=1, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=28 --> 1 | Trial completion date: Oct 2030 --> Mar 2027 | Trial primary completion date: Jul 2025 --> Dec 2022
- |||||||||| dexamethasone / Generic mfg., prednisone / Generic mfg.
Enrollment closed: High Dose Oral Steroids in Sudden Sensorineural Hearing Loss (clinicaltrials.gov) - Mar 9, 2023 P2, N=208, Active, not recruiting, Recruiting --> Active, not recruiting | N=28 --> 1 | Trial completion date: Oct 2030 --> Mar 2027 | Trial primary completion date: Jul 2025 --> Dec 2022 Recruiting --> Active, not recruiting
- |||||||||| Value for Money of Post-Market Surveillance of Medicines: Evidence from Indonesia () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1825;
We expect our findings to bring urgently needed and novel information on the cost and value-for-money of PMS. These may prove valuable for planning and budgeting to regulators and researchers in Indonesia and elsewhere, particularly in low- and middle-income settings, as well as international organisations working on health regulation.
- |||||||||| triamcinolone acetonide / Generic mfg.
Real-World Characterization and Management of Alopecia Areata Patients in the U.S. () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_869; Prevalence of diagnosed MDD was similar to the reported prevalence in U.S. adults, but GAD was higher (8.6% MDD and 2.7% GAD, NIMH Jan 2022). With new treatment options, tracking trends in disease and comorbidity burden in real-world care will be critical to understanding potential effects on quality of life.
- |||||||||| Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
Trial completion date, Trial termination, Combination therapy: Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab (clinicaltrials.gov) - Mar 8, 2023 P2, N=88, Terminated, Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2023 --> Mar 2024 Trial completion date: Feb 2026 --> Jan 2023 | Active, not recruiting --> Terminated; The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility.
- |||||||||| Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Biomarker, Trial completion date, Trial primary completion date, Metastases: NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Mar 8, 2023 P2, N=60, Suspended, Trial completion date: Feb 2026 --> Jan 2023 | Active, not recruiting --> Terminated; The decision was made to discontinue the 54767414MMY2065 study as the Data Review Committee recommendation was early stop of the study for futility. Trial completion date: Oct 2022 --> Apr 2024 | Trial primary completion date: Oct 2022 --> Apr 2024
- |||||||||| methylprednisolone oral / Generic mfg.
Review, Journal: Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial. (Pubmed Central) - Mar 8, 2023 The TESTING study, initiated in 2012, is an international, multicenter, double-blinded, randomized, placebo-controlled trial that aimed to evaluate oral methylprednisolone's safety and long-term efficacy under conditions of optimized supportive treatment in patients with IgAN whose risk of progression is high...Overall, the TESTING trial provided more data regarding the treatment dosage and safety of corticosteroids, a cost-effective therapy, in IgAN, which have important implications for pediatric patients with IgAN. With a deeper understanding of the disease pathogenesis of IgAN, ongoing studies of novel therapeutic regimens would help further optimize the benefit-risk ratio.
- |||||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg., Darzalex (daratumumab) / J&J
Retrospective data, Review, Journal: Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. (Pubmed Central) - Mar 7, 2023 The primary end-point was progression-free survival (PFS), evaluated as a hazard ratio (HR) with a 95% confidence interval (95% CI) compared to dexamethasone (DEX)...Daratumumab, lenalidomide and DEX was found to be the best treatment for RRMM, with the best HR compared to DEX (HR, 0.13; 95% CI, 0.08-0.20; p-score 0.9796). There was no evidence of significant heterogeneity (I , 41.3%; p
- |||||||||| Jakafi (ruxolitinib) / Novartis, Incyte
Journal: Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma. (Pubmed Central) - Mar 7, 2023 The combination of ruxolitinib and methylprednisolone demonstrated significant clinical activity among previously heavily-treated MM patients, and responses were achieved among patients who had high-risk cytogenetics. This is the first clinical study to show activity of JAK inhibitors in combination with steroids for MM patients and expands the potential use of these drugs to those with cancers other than myeloproliferative neoplasms.
|